However, since it does not account for cross-dose and changes to the marrow distribution when tumor infiltration is present, such an approach is less suitable for mCRPC patients with extensive bone disease, even though there is no specific uptake of [177Lu]Lu-PSMA-617 in bone marrow. The gene discussed is FOLH1; the disease is neoplasm.